AQAlberto Quistini

Alberto Quistini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alberto Quistini has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Marco Tozzi

    Department of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy

    3 shared publications
  • Massimiliano Depalma

    Department of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy

    3 shared publications
  • Matteo Ferro

    Department of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy

    3 shared publications
  • Roberto Bianchi

    Department of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy

    3 shared publications
  • Rocco Damiano

    Department of Urology, Magna Graecia University, Catanzaro, Italy

    3 shared publications
  • Francesco Chierigo

    Department of Urology University of Genoa, IRCCS Ospedale Policlinico San Martino Genoa Italy

    2 shared publications

Latest Publications

  • Outcomes of robot-assisted radical prostatectomy with novel robotic platforms vs da Vinci multiport systems: a systematic review and network meta-analysis

    by Francesco Chierigo, Giuseppe Fallara, Massimiliano Depalma, Marco Tozzi, Alberto Quistini, Roberto Bianchi, Martina Maggi, Guglielmo Mantica, Cosimo De Nunzio, Rocco Damiano, et al.

    Introduction The introduction of novel robotic platforms has expanded surgical options for robot-assisted radical prostatectomy (RARP). However, comparative outcomes with da Vinci multiport (MP) system remain unclear. This systematic review and network meta-analysis aimed to compare perioperative, early oncological, and functional outcomes of RARP performed with novel robotic platforms versus the da Vinci MP system. Methods A systematic literature search was conducted in PubMed, Scopus, and Embase (updated December 22, 2024) following PRISMA guidelines. Eligible studies compared RARP performed with alternative robotic platforms versus da Vinci MP, reporting perioperative, oncological, or functional outcomes. A network meta-analysis was conducted using a random-effects model. Outcomes were expressed as mean differences for continuous variables and odds ratios (OR) for dichotomous variables, with 95% confidence intervals (CI). Results Thirty-three studies for a total of 5987 patients were included. Compared to da Vinci MP, da Vinci SP had lower odds of lymph node dissection (OR 0.39, 95% CI 0.26–0.61) and nerve-sparing (OR 0.11, 95% CI 0.02–0.61) but was associated with shorter catheterization (−1.18 days, 95% CI −2.05 to -0.31) and hospital stay (−0.68 days, 95% CI −1.05 to −0.31). Versius, KangDuo, and SHURUI SP had significantly longer operative times (MD 74.00, 95% CI 42.49–105.51; MD 53.96, 95% CI 18.26–89.67; MD 103.88, 95% CI 69.99–137.78, respectively). Hugo RAS had higher intraoperative malfunction rates (OR 6.53, 95% CI 2.17–19.63). Positive surgical margin rates were lower for da Vinci SP (OR 0.70, 95% CI 0.53–0.92) but higher with the perineal approach (OR 6.30, 95% CI 1.53–25.94). PSA persistence, biochemical recurrence, continence and erectile function rates were comparable across platforms. Conclusion This is the first network meta-analysis comparing robotic platforms for RARP. While perioperative differences exist, oncological and functional outcomes appear comparable. Future studies should address learning curve effects, cost-effectiveness, and long-term functional outcomes to optimize robotic platform selection.


  • Open Access

    Comparative efficacy of combination therapy including regenerative therapies versus monotherapy for erectile dysfunction: A systematic review and meta‐analysis

    by Alberto Quistini, Giuseppe Fallara, Marco Tozzi, Massimiliano Depalma, Rocco Damiano, Alessandro Palmieri, Fabio Castiglione, Andrea Salonia, Roberto Bianchi, Matteo Ferro, et al.

    Background and objective: The Current European Association of Urology guidelines do not provide recommendation for combination of regenerative therapies with standard therapies for erectile dysfunction. The aim of this study was to compare the efficacy of combined regenerative therapy with monotherapy for erectile dysfunction. Methods: A systematic review and meta‐analysis were conducted following the 2020 Preferred Reporting Items for Systematic Reviews and Meta Analyses guidelines. The protocol was registered on PROSPERO (CRD42024522307). Randomized controlled trials and prospective/retrospective studies comparing combination therapies (low‐intensity external shockwave therapy, platelet‐rich plasma, stem cell therapy with phosphodiesterase‐5 inhibitors, or other treatments) with monotherapy were included. Erectile function was assessed using the International Index of Erectile Function‐5 and Erection Hardness Scale. Groups were compared using standardized mean difference. Subgroup analyses based on treatment type, erectile dysfunction cause, and follow‐up duration were also conducted. Risk of bias was assessed using risk of bias 2 and Robins‐I tools. Key findings and limitations: Of 1416 articles screened, eight studies involving 553 patients met the inclusion criteria. All studies included phosphodiesterase‐5 inhibitors and low‐intensity external shockwave therapy as regenerative treatment, with no studies on stem cell therapy or platelet‐rich plasma. After treatment, no significant difference in International Index of Erectile Function scores was found between combination and monotherapy groups. However, subgroup analysis revealed that combination therapy showed a statistically significant improvement compared to low‐intensity external shockwave therapy alone (standardized mean difference: 0.61; 95% confidence interval: 0.13‒1.09; p = 0.013). A statistically significant improvement was found in vasculogenic (standardized mean difference: 0.65; p < 0.001) and diabetic cases (standardized mean difference: 1.05; p < 0.001). Conclusions and clinical implications: Combination of phosphodiesterase‐5 inhibitors and intensity external shockwave therapy resulted in significant improvement of International Index of Erectile Function compared to intensity external shockwave therapy alone. However, the risk of bias was high because of the low quality of the studies. Patient summary: Combination of phosphodiesterase‐5 inhibitor with intensity external shockwave therapy significantly improved erectile function, especially in patients with vasculogenic erectile dysfunction or diabetes.


  • Top Cited Papers
    Open Access

    Androgen Receptor Signalling in Prostate Cancer: Mechanisms of Resistance to Endocrine Therapies

    by Alberto Quistini, Francesco Chierigo, Giuseppe Fallara, Massimiliano Depalma, Marco Tozzi, Martina Maggi, Letizia Maria Ippolita Jannello, Francesco Pellegrino, Guglielmo Mantica, Daniela Terracciano, et al.

    Prostate cancer (PCa) is a major global health concern. It ranks as the fifth leading cause of cancer-related mortality worldwide. While localized PCa is often indolent, with a nearly 100% five-year survival rate, prognosis worsens significantly in metastatic disease, where survival drops to approximately 30%. Androgen deprivation therapy (ADT) is initially effective in suppressing tumor growth. However, resistance eventually develops, resulting in castration-resistant prostate cancer (CRPC). The androgen receptor (AR) plays a central role in both PCa progression and treatment resistance. It promotes tumor growth by mediating the effects of testosterone and 5α-dihydrotestosterone (DHT). Several mechanisms contribute to resistance. These include AR gene mutations that reduce ligand specificity or convert antagonists into agonists. AR overexpression can maintain activity even at low androgen levels. Splice variants such as AR-V7 can activate AR signaling despite androgen depletion. AR transcriptional activity is also modulated by coregulators. Coactivators (such as the SRC family) and corepressors (such as NCOR1/2) contribute to the persistence of AR signaling. Beyond AR-dependent mechanisms, CRPC may develop through AR-independent pathways. These include glucocorticoid receptor (GR) bypass signaling and lineage plasticity leading to neuroendocrine prostate cancer (NEPC). In addition, intratumoral steroidogenesis sustains AR activation despite systemic suppression of androgens. Together, these resistance mechanisms underscore the biological complexity of CRPC. They also highlight the urgent need for innovative therapeutic approaches. This manuscript reviews emerging molecular targets and resistance pathways to inform the development of next-generation treatments.